CANNABIS POLAND AB ZY-10 (8TE) - Net Assets
Based on the latest financial reports, CANNABIS POLAND AB ZY-10 (8TE) has net assets worth €1.52 Million EUR (≈ $1.78 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.01 Million ≈ $3.52 Million USD) and total liabilities (€1.49 Million ≈ $1.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of CANNABIS POLAND AB ZY-10 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.52 Million |
| % of Total Assets | 50.61% |
| Annual Growth Rate | 33.41% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 154.01 |
CANNABIS POLAND AB ZY-10 - Net Assets Trend (2021–2025)
This chart illustrates how CANNABIS POLAND AB ZY-10's net assets have evolved over time, based on quarterly financial data. Also explore 8TE total assets for the complete picture of this company's asset base.
Annual Net Assets for CANNABIS POLAND AB ZY-10 (2021–2025)
The table below shows the annual net assets of CANNABIS POLAND AB ZY-10 from 2021 to 2025. For live valuation and market cap data, see CANNABIS POLAND AB ZY-10 (8TE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.52 Million ≈ $1.78 Million |
-56.94% |
| 2024-12-31 | €3.54 Million ≈ $4.14 Million |
+161.02% |
| 2023-12-31 | €1.36 Million ≈ $1.58 Million |
+320.99% |
| 2022-12-31 | €321.96K ≈ $376.41K |
-33.04% |
| 2021-12-31 | €480.84K ≈ $562.15K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CANNABIS POLAND AB ZY-10's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 581753371.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €15.69 Million | 1030.07% |
| Total Equity | €1.52 Million | 100.00% |
CANNABIS POLAND AB ZY-10 Competitors by Market Cap
The table below lists competitors of CANNABIS POLAND AB ZY-10 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Northcliff Citranusa Indonesia Tbk PT
JK:SKYB
|
$1.75 Million |
|
Canada Carbon Inc.
V:CCB
|
$1.75 Million |
|
Colibri Resource Corp
V:CBI
|
$1.75 Million |
|
Portofino Resources Inc
V:POR
|
$1.75 Million |
|
Warpaint London PLC
LSE:W7L
|
$1.74 Million |
|
KATORO GOLD PLC LS-01
F:622
|
$1.74 Million |
|
Heads UP Ventures Limited
NSE:HEADSUP
|
$1.74 Million |
|
Fram Skandinavien AB Series B
ST:FRAM-B
|
$1.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CANNABIS POLAND AB ZY-10's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,465,508 to 1,523,308, a change of -1,942,200 (-56.0%).
- Net loss of 1,942,200 reduced equity.
- New share issuances of 209,900 increased equity.
- Other factors decreased equity by 209,900.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.94 Million | -127.5% |
| Share Issuances | €209.90K | +13.78% |
| Other Changes | €-209.90K | -13.78% |
| Total Change | €- | -56.04% |
Book Value vs Market Value Analysis
This analysis compares CANNABIS POLAND AB ZY-10's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.66x to 0.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.02 | €0.03 | x |
| 2022-12-31 | €0.01 | €0.03 | x |
| 2023-12-31 | €0.03 | €0.03 | x |
| 2024-12-31 | €0.06 | €0.03 | x |
| 2025-12-31 | €0.03 | €0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CANNABIS POLAND AB ZY-10 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -127.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -919.50%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.98x
- Recent ROE (-127.50%) is above the historical average (-132.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -163.98% | -206.87% | 0.58x | 1.37x | €-836.59K |
| 2022 | -230.55% | -338.00% | 0.30x | 2.27x | €-705.07K |
| 2023 | -82.54% | -2117.16% | 0.03x | 1.31x | €-1.30 Million |
| 2024 | -58.99% | -816.71% | 0.06x | 1.21x | €-2.39 Million |
| 2025 | -127.50% | -919.50% | 0.07x | 1.98x | €-2.09 Million |
Industry Comparison
This section compares CANNABIS POLAND AB ZY-10's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $864,774,940
- Average return on equity (ROE) among peers: -84.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CANNABIS POLAND AB ZY-10 (8TE) | €1.52 Million | -163.98% | 0.98x | $1.75 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| Apontis Pharma AG (APPH) | $40.71 Million | -1.83% | 0.33x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About CANNABIS POLAND AB ZY-10
Cannabis Poland S.A. operates in the medical cannabis industry in Poland. The company distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals. It sells its products through HempWish.pl and Vapem.eu online stores. The company also engages in the research and development of CBD-based drugs based on scienti… Read more